Movement Alert｜AKESO Rises 4.15% in Regular Trading, Ivonescimab Global Phase III OS Data Continues to Improve with New Renal Cancer Collaboration

Market Focus07-23

On July 23, AKESO rose 4.15% in regular trading, trading at 104.3 HKD/share, with turnover of HKD 371 million. The stock was driven by multiple positive catalysts from its overseas partner Summit Therapeutics.

Summit recently disclosed the latest OS analysis from the global multi-center Phase III HARMONi study of ivonescimab: OS hazard ratios in both the ITT population and Western population improved to 0.76, highly consistent with the China HARMONi-A study results. The data has been submitted to the FDA to support BLA review. On the same day, Summit announced a collaboration with Arcus Biosciences to advance ivonescimab in combination with HIF-2alpha inhibitor casdatifan for clear cell renal cell carcinoma in an international multi-center clinical study, further expanding the indication landscape for ivonescimab.

These developments follow a series of recent catalysts for AKESO, including the first patient dosing in a Phase II study of its novel Trop2/Nectin-4 bispecific ADC combined with ivonescimab for advanced NSCLC, advancing the company's IO2.0 plus ADC2.0 dual-platform strategy.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1161526938?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-23 11:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1161526938","market":"us","top_or_hot":-1,"title":"Movement Alert｜AKESO Rises 4.15% in Regular Trading, Ivonescimab Global Phase III OS Data Continues to Improve with New Renal Cancer Collaboration","media":"Market Focus","content":"<p><p>On July 23, AKESO rose 4.15% in regular trading, trading at 104.3 HKD/share, with turnover of HKD 371 million. The stock was driven by multiple positive catalysts from its overseas partner Summit Therapeutics.</p><p>Summit recently disclosed the latest OS analysis from the global multi-center Phase III HARMONi study of ivonescimab: OS hazard ratios in both the ITT population and Western population improved to 0.76, highly consistent with the China HARMONi-A study results. The data has been submitted to the FDA to support BLA review. On the same day, Summit announced a collaboration with Arcus Biosciences to advance ivonescimab in combination with HIF-2alpha inhibitor casdatifan for clear cell renal cell carcinoma in an international multi-center clinical study, further expanding the indication landscape for ivonescimab.</p><p>These developments follow a series of recent catalysts for AKESO, including the first patient dosing in a Phase II study of its novel Trop2/Nectin-4 bispecific ADC combined with ivonescimab for advanced NSCLC, advancing the company's IO2.0 plus ADC2.0 dual-platform strategy.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜AKESO Rises 4.15% in Regular Trading, Ivonescimab Global Phase III OS Data Continues to Improve with New Renal Cancer Collaboration</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜AKESO Rises 4.15% in Regular Trading, Ivonescimab Global Phase III OS Data Continues to Improve with New Renal Cancer Collaboration\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-23 11:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 23, AKESO rose 4.15% in regular trading, trading at 104.3 HKD/share, with turnover of HKD 371 million. The stock was driven by multiple positive catalysts from its overseas partner Summit Therapeutics.</p><p>Summit recently disclosed the latest OS analysis from the global multi-center Phase III HARMONi study of ivonescimab: OS hazard ratios in both the ITT population and Western population improved to 0.76, highly consistent with the China HARMONi-A study results. The data has been submitted to the FDA to support BLA review. On the same day, Summit announced a collaboration with Arcus Biosciences to advance ivonescimab in combination with HIF-2alpha inhibitor casdatifan for clear cell renal cell carcinoma in an international multi-center clinical study, further expanding the indication landscape for ivonescimab.</p><p>These developments follow a series of recent catalysts for AKESO, including the first patient dosing in a Phase II study of its novel Trop2/Nectin-4 bispecific ADC combined with ivonescimab for advanced NSCLC, advancing the company's IO2.0 plus ADC2.0 dual-platform strategy.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09926","symbol_name":"康方生物","start_time":0,"source_url":"","article_id":"1161526938","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1161526938","pubTimestamp":1784775882,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 23, AKESO rose 4.15% in regular trading, trading at 104.3 HKD/share, with turnover of HKD 371 million. The stock was driven by multiple positive catalysts from its overseas partner Summit...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09926":"康方生物"},"translate_title":"走势提醒|AKESO常规交易涨4.15%，Ivonescimab全球III期OS数据持续向好，肾癌新合作","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09926":1},"content_text":"On July 23, AKESO rose 4.15% in regular trading, trading at 104.3 HKD/share, with turnover of HKD 371 million. The stock was driven by multiple positive catalysts from its overseas partner Summit Therapeutics.Summit recently disclosed the latest OS analysis from the global multi-center Phase III HARMONi study of ivonescimab: OS hazard ratios in both the ITT population and Western population improved to 0.76, highly consistent with the China HARMONi-A study results. The data has been submitted to the FDA to support BLA review. On the same day, Summit announced a collaboration with Arcus Biosciences to advance ivonescimab in combination with HIF-2alpha inhibitor casdatifan for clear cell renal cell carcinoma in an international multi-center clinical study, further expanding the indication landscape for ivonescimab.These developments follow a series of recent catalysts for AKESO, including the first patient dosing in a Phase II study of its novel Trop2/Nectin-4 bispecific ADC combined with ivonescimab for advanced NSCLC, advancing the company's IO2.0 plus ADC2.0 dual-platform strategy.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1161526938","isCrawlerRequest":true}